Retraction: Festuccia, C., Gravina, G. L., Angelucci, A., Millimaggi, D., Muzi, P., Vicentini, C. and Bologna, M. (2005), Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro. Int. J. Cancer, 115: 630–640. http://bit.ly/2DByr9Z.

The above article, published online on 7 February 2005, in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the authors, the journal Editor‐in‐Chief, Prof. Peter Lichter, the Union for International Cancer Control and John Wiley & Sons, Ltd. The retraction has been agreed due to reuse of several figure panels in the paper. Due to the time elapsed since the publication of the article, the original data for these figures are no longer available for re‐analysis. The authors are therefore not able to confirm the accuracy of the reported results or provide updated figures to replace the duplicated panels.

Reference

International Journal of Cancer

Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro

Volume 115, Issue 4, 1 July 2005, Pages: 630–640, Claudio Festuccia, Giovanni Luca Gravina, Adriano Angelucci, Danilo Millimaggi, Paola Muzi, Carlo Vicentini and Mauro Bologna

Version of Record online : 7 FEB 2005, DOI: https://doi.org/10.1002/ijc.2091710.1002/ijc.20917

http://bit.ly/2Svr6mE